Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDOST | P39656 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRHR | P34981 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513480 | 1.00 | DDOST (0.43) | DDOSTPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11735638 | 1.00 | DDOST (0.43) | DDOSTPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25834354 | 0.88 | POLB (0.42) | POLBSMN1; SMN2MEN1KMT2ATRHR | |
| SCHEMBL14943195 | 0.88 | POLB (0.42) | POLBSMN1; SMN2MEN1KMT2ATRHR | |
| SCHEMBL20560032 | 0.87 | SMN1; SMN2 (0.42) | POLBSMN1; SMN2MEN1KMT2AACACB | |
| SCHEMBL2597779 | 0.87 | SMN1; SMN2 (0.42) | POLBSMN1; SMN2MEN1KMT2AACACB | |
| SCHEMBL2597780 | 0.87 | SMN1; SMN2 (0.42) | POLBSMN1; SMN2MEN1KMT2AACACB | |
| SCHEMBL11737947 | 0.86 | TRHR (0.38) | DDOSTPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18818408 | 0.85 | POLB (0.42) | POLBSMN1; SMN2MEN1KMT2ATRHR | |
| SCHEMBL11738722 | 0.85 | POLB (0.42) | POLBSMN1; SMN2MEN1KMT2ATRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3429996-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-109153644-A | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H·李·莫菲特癌症中心研究有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | DDOST 964/4885POLB 4576/4885SMN1; SMN2 2324/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | DDOST 861/4885POLB 4464/4885SMN1; SMN2 1305/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | DDOST 513/4885POLB 4402/4885SMN1; SMN2 1822/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | DDOST 861/4885POLB 4464/4885SMN1; SMN2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.